Cumberland Pharmaceuticals (NASDAQ:CPIX) Share Price Crosses Above 200 Day Moving Average - What's Next?

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX - Get Free Report) shares passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $3.25 and traded as high as $4.86. Cumberland Pharmaceuticals shares last traded at $4.54, with a volume of 20,291 shares traded.

Wall Street Analyst Weigh In

Separately, StockNews.com raised Cumberland Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Thursday, March 6th.

Cumberland Pharmaceuticals Price Performance

The firm has a market capitalization of $63.41 million, a PE ratio of -5.90 and a beta of -0.35. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.99 and a current ratio of 1.13. The stock has a fifty day moving average price of $4.76 and a 200-day moving average price of $3.25.

Cumberland Pharmaceuticals (NASDAQ:CPIX - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $0.15 earnings per share (EPS) for the quarter. Cumberland Pharmaceuticals had a negative return on equity of 9.50% and a negative net margin of 29.54%.

Hedge Funds Weigh In On Cumberland Pharmaceuticals

A hedge fund recently raised its stake in Cumberland Pharmaceuticals stock. Two Sigma Investments LP increased its position in shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX - Free Report) by 94.3% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 37,649 shares of the specialty pharmaceutical company's stock after purchasing an additional 18,271 shares during the quarter. Two Sigma Investments LP owned approximately 0.27% of Cumberland Pharmaceuticals worth $89,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 15.51% of the company's stock.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.